Profund Advisors LLC Boosts Position in Janux Therapeutics, Inc. $JANX

Profund Advisors LLC increased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 289.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,022 shares of the company’s stock after purchasing an additional 47,584 shares during the quarter. Profund Advisors LLC’s holdings in Janux Therapeutics were worth $884,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in JANX. Orbimed Advisors LLC lifted its stake in Janux Therapeutics by 45.9% during the third quarter. Orbimed Advisors LLC now owns 1,766,100 shares of the company’s stock worth $43,163,000 after purchasing an additional 555,800 shares during the last quarter. Readystate Asset Management LP lifted its stake in Janux Therapeutics by 38.0% during the third quarter. Readystate Asset Management LP now owns 960,379 shares of the company’s stock worth $23,472,000 after purchasing an additional 264,423 shares during the last quarter. Vanguard Group Inc. lifted its stake in Janux Therapeutics by 10.4% in the third quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock valued at $59,074,000 after buying an additional 227,676 shares during the last quarter. Wellington Management Group LLP lifted its stake in Janux Therapeutics by 42.5% in the third quarter. Wellington Management Group LLP now owns 701,604 shares of the company’s stock valued at $17,147,000 after buying an additional 209,243 shares during the last quarter. Finally, UBS Group AG lifted its stake in Janux Therapeutics by 51.2% in the fourth quarter. UBS Group AG now owns 590,060 shares of the company’s stock valued at $8,143,000 after buying an additional 199,703 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on JANX shares. Cantor Fitzgerald reduced their price objective on Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Piper Sandler reduced their price objective on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Evercore set a $22.00 price objective on Janux Therapeutics in a research note on Monday, May 11th. Guggenheim reduced their price objective on Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, April 5th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.85.

Janux Therapeutics Trading Up 0.1%

NASDAQ:JANX opened at $14.41 on Friday. The firm has a market cap of $878.78 million, a P/E ratio of -7.83 and a beta of 2.58. The stock’s 50 day simple moving average is $14.44 and its 200-day simple moving average is $16.54. Janux Therapeutics, Inc. has a 12-month low of $12.12 and a 12-month high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.13. The company had revenue of $3.73 million during the quarter, compared to analyst estimates of $4.36 million. Research analysts forecast that Janux Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.

Insider Activity

In other news, VP Maria Dobek sold 2,038 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $14.17, for a total value of $28,878.46. Following the transaction, the vice president owned 32,270 shares of the company’s stock, valued at approximately $457,265.90. The trade was a 5.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 7.90% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.